Skip to main content
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRV ISIN · US0048901096 US Manufacturing
Open in API
Filings indexed 293 across all filing types
Latest filing 2024-03-29 Regulatory Filings
Country US United States of America
Listing US ACRV

About Acrivon Therapeutics, Inc.

https://acrivon.com/

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company's core technology is its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which uses proteomics to identify the biologic drivers of cancer in individual patients. This platform enables the development of OncoSignature companion diagnostic tests designed to match patients with therapies predicted to be most effective for their specific tumor biology, a method distinct from genomic-based approaches. Acrivon's pipeline focuses on DNA Damage Response and cell cycle regulators. Its lead drug candidate, ACR-368 (prexasertib), is a selective kinase inhibitor in Phase 2 clinical trials for multiple solid tumor types. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor. The company leverages its AP3 platform for internal drug development and for strategic co-development partnerships.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes details about the number of shares registered, references to prior registration statements, incorporation by reference of other filings like the Annual Report on Form 10-K, and exhibits related to corporate governance documents and legal opinions. The document is not a financial report, earnings release, or management discussion but a regulatory filing specifically for securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS).
2024-03-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 28, 2024, reporting the issuance of a press release announcing financial results for the fourth quarter and full year ended December 31, 2023. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the document itself does not contain detailed financial statements or substantive financial data. The length is 3520 characters, which is relatively short and consistent with a report publication or announcement rather than a full earnings release. The document is primarily an announcement of the earnings release, not the earnings release itself. Therefore, according to the MENU VS MEAL RULE and the nature of Form 8-K Item 2.02 filings, this document should be classified as Regulatory Filings (RNS).
2024-03-28 English
10-K
Annual Report FY 2023
2024-03-28 English
Director's Dealing 2024
Director's Dealing
2024-03-06 English
Director's Dealing 2024
Director's Dealing
2024-03-06 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the appointment of a new director to the company's board, including details about the director's compensation and indemnification agreement. There is no financial data or detailed report content, but rather an announcement of a management change. This fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and it is not a report publication announcement or certification. Therefore, the correct classification is MANG with high confidence.
2024-03-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.